Results 151 to 160 of about 8,795,233 (257)

Long‐Term Prognosis, Residual Recurrence Risk, and Postoperative Management After Pathological Complete Response in Rectal Cancer

Cancer Nexus, EarlyView.
This graphical abstract summarizes the post‐pCR clinical pathway in locally advanced rectal cancer. After neoadjuvant radiotherapy and systemic therapy followed by surgery, patients achieving pCR (ypT0N0) generally have durable disease control, although residual risks of local and distant recurrence remain. Risk assessment, guideline‐based surveillance,
Jia‐ang Wang, Yingjiang Ye, Zhidong Gao, Sen Hou   +3 more
wiley   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Gupta S, Sarangi S, Jaiswal A, Lattoo MR, Rajpurohit S, Mittal D, Lamin JCA, Durga T, Yadav R, Ahmad Y.   +9 more
europepmc   +1 more source

Lymph Node Harvest and Prognosis in Stage II-III Rectal Cancer in the Era of Total Neoadjuvant Therapy

BACKGROUND: Current guidelines recommend the examination of a minimum of 12 lymph nodes following rectal cancer resection.
Paolo Goffredo, Sarah L. Mott, Catherine Tran, Imran Hassan, Janet S. Lee, Julia Frebault, Wolfgang Gaertner, Pridvi Kandagatla   +7 more
core   +1 more source

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

American Journal of Hematology, EarlyView.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source

Organ preservation with total neoadjuvant therapy in early-stage rectal cancer: A statewide analysis. [PDF]

Colorectal Dis
Bunjo Z, Fitzsimmons T, Nguyen TM, Penniment M, Selva-Nayagam S, Tonkin D, Sia TC, Murphy E, Thomas M, Sammour T.   +9 more
europepmc   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy. [PDF]

Cancer Med
Li S, Yan M, Ma Q, Sun Y, Zhang Z, Shen L, Wan J, Zhang H, Wu R, Xia F, Wang Y.   +10 more
europepmc   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source